Efficacy of larotrectinib in pediatric cancers with NTRK gene fusions
Peter J. Houghton, Mary-Ann Bjornsti · 2025
Read Efficacy of larotrectinib in pediatric cancers with NTRK gene fusions by Peter J. Houghton, Mary-Ann Bjornsti (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12771222.txt.
Description
Peter Houghton and Mary-Ann Bjornsti wrote a 2025 review on a drug called larotrectinib for cancers in children. The drug targets tumors driven by fusions of genes called NTRK. In a fusion, the front of one gene joins the back of an NTRK gene, and the joined gene stays switched on and drives growth.
The review explains how these fusions form and how the drug blocks the faulty signal. In healthy growth, the same genes help nerve cells form and wire the brain. In cancer, more than 80 partner genes can fuse with an NTRK gene. The authors weigh what is known about how well the drug works in young patients. Their review helps readers see why gene tests matter before this kind of care is chosen.
Catalog record
| CREATOR | Peter J. Houghton, Mary-Ann Bjornsti |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 11 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |